Profile data is unavailable for this security.
About the company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
- Revenue in USD (TTM)0.00
- Net income in USD-245.60m
- Incorporated1999
- Employees268.00
- LocationRocket Pharmaceuticals Inc350 5th Ave Ste 7530NEW YORK 10118-7501United StatesUSA
- Phone+1 (646) 440-9100
- Fax+1 (781) 676-2155
- Websitehttps://www.rocketpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.96bn | 383.00 | -- | 2.63 | -- | 66.69 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Ardelyx Inc | 124.46m | -66.07m | 2.03bn | 267.00 | -- | 12.15 | -- | 16.30 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.07bn | 1.76k | 16.41 | 3.19 | 11.69 | 3.22 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Amneal Pharmaceuticals Inc | 2.39bn | -83.99m | 2.09bn | 7.70k | -- | 156.75 | 11.54 | 0.8714 | -0.3116 | -0.3116 | 13.46 | 0.0431 | 0.6583 | 2.83 | 3.53 | 310,858.10 | -1.34 | -4.80 | -1.70 | -5.93 | 34.28 | 34.76 | -2.04 | -9.00 | 0.9408 | 1.14 | 0.9778 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.09bn | 355.00 | -- | 5.82 | -- | 12.78 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 2.10bn | 500.00 | -- | 4.46 | -- | 47.10 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -245.60m | 2.12bn | 268.00 | -- | 4.30 | -- | -- | -2.94 | -2.94 | 0.00 | 5.46 | 0.00 | -- | -- | 0.00 | -43.93 | -35.26 | -47.67 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0412 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Keros Therapeutics Inc | 151.00k | -152.99m | 2.18bn | 136.00 | -- | 5.81 | -- | 14,467.72 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.24bn | 445.00 | -- | 3.38 | -- | 28.56 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.26bn | 650.00 | -- | 5.41 | -- | 7.82 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Intellia Therapeutics Inc | 36.28m | -481.19m | 2.27bn | 526.00 | -- | 2.09 | -- | 62.53 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dyne Therapeutics Inc | 0.00 | -257.40m | 2.28bn | 143.00 | -- | 4.75 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.29bn | 186.00 | -- | 3.23 | -- | 28.90 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.30bn | 1.78k | -- | 14.47 | -- | 4.08 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Data as of May 03 2024. Currency figures normalised to Rocket Pharmaceuticals Inc's reporting currency: US Dollar USD
60.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Dec 2023 | 17.69m | 19.54% |
| Wellington Management Co. LLPas of 29 Mar 2024 | 9.16m | 10.12% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.26m | 5.82% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.83m | 5.34% |
| Maverick Capital Ltd.as of 31 Dec 2023 | 4.03m | 4.46% |
| Westfield Capital Management Co. LPas of 31 Dec 2023 | 3.94m | 4.36% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.23m | 3.57% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.56m | 2.83% |
| Citadel Advisors LLCas of 31 Dec 2023 | 2.45m | 2.71% |
| Avidity Partners Management LPas of 31 Dec 2023 | 1.72m | 1.90% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
